Introduction {#s1}
============

Irisin is a peptide produced by proteolytic cleavage of fibronectin type III domain-containing protein 5 (FNDC5), a membrane-bound protein highly expressed in the skeletal muscle. *FNDC5* expression increases in response to acute bouts of exercise by regulation of PGC-1α, leading to a burst of circulating irisin ([@bib13]). Initially, irisin was described as a hormone that induces thermogenesis in adipose tissue ([@bib3]), but more recent studies have shown that it has a potent ability to modulate bone turnover. These effects support the tenet that irisin may be a key mediator of muscle-bone crosstalk during exercise. Initial studies demonstrated that irisin enhanced cortical bone formation and prevented unloading-induced bone loss in vivo and stimulated osteoblasts in vitro ([@bib4]; [@bib5]; [@bib6]). Conversely, genetic deletion of *Fndc5* was separately shown to block resorption-driven bone loss and maintain osteocyte function following ovariectomy; irisin treatment in vitro also prevented osteocyte apoptosis and stimulated sclerostin and RANKL release, key promoters of osteoclastogenesis, through the α~V~β~5~ integrin receptor ([@bib14]). This study addresses the hypothesis that irisin also directly stimulates osteoclast differentiation and function in vitro and in vivo.

Results and discussion {#s2}
======================

First, we used continuous treatment with a range of irisin doses (0, 2, 5, 10, and 20 ng/mL) for 7 days in an in vitro osteoclast differentiation assay using primary marrow hematopoietic progenitors. These doses were based on previous studies establishing the physiologic range of circulating irisin during and after exercise ([@bib13]). We found a qualitative enhancement of both osteoclast number and size ([Figure 1a](#fig1){ref-type="fig"}), and significant increases in osteoclast number across this dose range (2, 5, and 10 ng/mL: p\<0.0001, 20 ng/mL: p=0.044; [Figure 1b](#fig1){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). Based on these results, we selected 10 ng/mL irisin to compare continuous (7 days) and transient treatment for the first 4 or 24 hr of culture, and for all further experiments with resorption and gene expression. Both transient treatments led to enhanced osteoclast numbers versus controls (4 hr: p=0.0218, 24 hr: p=0.0008), but continuous irisin resulted in the greatest increase (p\<0.0001) and was higher than both 4 hr (p=0.0002) and 24 hr only treatments (p=0.0152; [Figure 1c](#fig1){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). The stimulatory effect of continuous 10 ng/mL irisin was then further confirmed in primary hematopoietic cells from both sexes of C57BL/6J mice (p=0.0003) and in the RAW 264.7 macrophage cell line (p=0.0428; [Figure 1d](#fig1){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). RAW-derived osteoclasts appeared morphologically similar to primary cells and mirrored observations of qualitatively larger cells with irisin treatment ([Figure 1e](#fig1){ref-type="fig"}).

![Representative 10× and 40× (boxed inset) images of TRAP-positive stained osteoclasts after 7-day differentiation with 10 ng/mL irisin (ISN) or untreated controls (CTL) (**a**).\
Quantification of osteoclasts per well demonstrating enhanced osteoclastogenesis in response to continuous irisin across a physiologic range of 2--20 ng/mL (**b**, N = 6) and to treatment with 10 ng/mL irisin for only first 4 or 24 hr of culture compared to continuous treatment or CTL (**c**, N = 6--8). Quantification of osteoclasts per well confirming irisin stimulation of osteoclastogenesis with continuous 10 ng/mL treatment across primary murine gender with female BL6 mice, and with the macrophage cell line RAW 264.7 (**d**, N = 8), with representative images of differentiated RAW-derived osteoclasts (**e**). Expression of integrin receptor subunit αV (ITGAV) and β5 (ITGB5) in primary osteoclast cultures normalized to *Hprt* (**f**, N = 3), and quantification of osteoclast per well counts for CTL or continuous 10 ng/mL ISN in the presence of integrin αVβ5 neutralizing antibody (AVB5-AB), an IgG antibody control (IgG), or no antibody (CTL) (**g**, N = 5--6). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001, not significant (NS) versus CTL within-group or as indicated.](elife-58172-fig1){#fig1}

As integrins are present on the osteoclast membrane and known to play a role in differentiation ([@bib10]; [@bib24]), and earlier work identified integrin α~V~β~5~ as a receptor for irisin on osteocytes ([@bib14]), we examined the expression of both subunits in osteoclast cultures and found increased relative mRNA expression above controls with irisin treatment (α~V~: p=0.552, β~5~: p=0.031; [Figure 1f](#fig1){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). Blocking integrin α~V~β~5~ with a neutralizing antibody (AVB5-AB) resulted in no differences in osteoclast number per well with irisin treatment (10 ng/mL) versus untreated controls (p=0.79) compared to significant increases with an IgG antibody control (p=0.012) or no-antibody conditions (p=0.0295), indicating this integrin acts as the receptor for irisin on osteoclasts ([Figure 1g](#fig1){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}).

Next, we asked whether irisin-induced osteoclastogenesis led to enhanced bone resorption. Osteoclast differentiation cultures were performed on a variety of native and synthetic substrates with and without continuous 10 ng/mL irisin. TRAP-positive osteoclasts were observed in situ on dentin slices after 7 days ([Figure 2a](#fig2){ref-type="fig"}, left), and subsequent toluidine blue staining revealed a qualitative increase in resorption pit area on the surface with irisin treatment ([Figure 2a](#fig2){ref-type="fig"}, right). Irisin significantly increased osteoclast numbers on dentin (p=0.013), as well as total resorption area (p=0.045). However, when normalized by osteoclast number, resorption was not significantly different (p\>0.99), indicating a dominant effect of cell number in increasing total resorption ([Figure 2b](#fig2){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). Irisin enhancement of total resorption was further confirmed via the Corning OsteoAssay, with a similar significant increase in total resorption area (p=0.048; [Figure 2c](#fig2){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). Release of carboxy-terminal collagen crosslinks (CTX) from osteoclast cultures on collagen substrates was measured to assess the effect of transient irisin treatment on resorption at early stages in culture and was significantly increased with both continuous irisin treatment for 3 days (p=0.0153) and for the first 24 hr only (p\<0.0001), with this transient treatment also resulting in significantly higher resorption than continuous treatment (p=0.0041; [Figure 2d](#fig2){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}).

![Representative images of TRAP-positive osteoclasts on dentin after 7-day osteoclast culture (left), and underlying resorption pits (arrows) stained with toluidine blue dye after decellularization via sonication, demonstrating increased resorption with irisin treatment (ISN) versus untreated controls (CTL) (**a**).\
Quantification of osteoclast number, total resorption area, and resorption normalized to osteoclast number for dentin cultures (**b**, N = 3--4). Confirmation of irisin stimulation of resorption with Corning OsteoAssay resorbable calcium phosphate substrate, representative full-diameter images of 96-well plates with binary threshold to visualized resorption pits on von Kossa-stained substrate after 7-day osteoclast culture for ISN versus CTL, with quantification of total resorption by percent area (**c**, N = 8). Irisin stimulation of early-stage resorption with transient treatment for the first 24 hr alone, versus continuous ISN and CTL with quantification of resorption determined by ELISA of CTX release into media collected at day 3 of culture (**d**, N = 5). \*p\<0.05 versus CTL, \*\*p\<0.01, \*\*\*\*p\<0.0001, not significant (NS) versus CTL within-group or as indicated.](elife-58172-fig2){#fig2}

To investigate the key signaling pathways influenced by the action of irisin on the osteoclast, we performed an unbiased analysis of RNA sequencing (RNAseq) data from in vitro osteoclast cultures after 7 days of continuous 10 ng/mL irisin treatment, which demonstrated a qualitatively differential gene expression pattern compared to untreated controls, as typified by hierarchical clustering, volcano plot, and principal component analysis ([Figure 3a](#fig3){ref-type="fig"}). Irisin treatment significantly increased the expression of resorption markers *Adamts5* (p=0.0381) and *Loxl2* (p=0.009), and markers for secreted clastokines known to stimulate osteoblasts: *Postn* (p=0.0002), *Igfbp5* (p=0.03), *Tgfb2* (p=0.0073), and *Sparc* (p=0.0365). Significant decreases in the expression of macrophage markers *Mst1r* (p=0.0416) and *Itgax* (p\<0.0001) and the lymphocyte markers *Cd72* (p=0.0086), *Slamf8* (p=0.0052), and *H2-aa* (p=0.0017) indicated a preferential shift of the hematopoietic progenitor lineage toward osteoclast differentiation ([Source data 1](#sdata1){ref-type="supplementary-material"}). RT-qPCR further showed that irisin significantly increased the expression of key differentiation markers, namely, *Rank*, the receptor for RANKL (p=0.019), *c-src* (p=0.008), *Fam102a* (p=0.039), *Nrf2* (p=0.0008), and the osteoclast fusion markers *Dcstamp* (p=0.0039) and *Atp6vod2* (p=0.012). Other early markers of osteoclast differentiation such as *Cfos* (p=0.41), *Itgb3* (p=0.09), *Nfatc* (p=0.11), *Rela* (p=0.12), and *Rgs12* (p=0.09) were slightly but not significantly increased. Significant increases were confirmed for both key resorption markers: *Acp5* (p=0.012) and *Loxl2* (p=0.035), and clastokine markers: *Sparc* (p=0.009) and *Wnt10a* (p=0.047; [Figure 3b](#fig3){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}).

![RNAseq analysis of differential gene expression pattern induced by continuous 10 ng/mL irisin treatment (ISN) compared to untreated controls (CTL) at day 7, as typified by representative sample hierarchical clustering, volcano plot, and principal component analysis (**a**, N = 2).\
Relative mRNA expression quantified by RT-qPCR of markers for osteoclast differentiation, resorption, and clastokines in irisin-treated osteoclasts (ISN) compared to untreated controls (CTL), normalized to *Hprt* expression (**b**, N = 3--6). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 versus CTL within gene.](elife-58172-fig3){#fig3}

Next, we turned to a genetic model of forced expression of *Fndc5* in C57BL/6J mice using the *McK* muscle-specific promoter. RT-qPCR analysis of the whole tibia demonstrated a significant increase in *Fndc5* expression at both 4.5 months (p=0.000082) and 13 months (p=0.0041), indicating promoter activity in the bone marrow in addition to the muscle ([Figure 4a](#fig4){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). Markedly lower cortical bone area was observed by µCT at younger ages in *Fndc5*-transgenic (TG) mice compared to wild type (WT) (2 and 4.5 months), with significant decreases in trabecular bone volume fraction at 2 (p\<0.0001) and 4.5 months (p=0.0003) and in cortical thickness at 2 months (p\<0.0001; [Figure 4b](#fig4){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). Dynamic histomorphometry revealed smaller bones and similar decreases in overall bone volume fraction and trabecular thickness that persisted from 2 to 13 months ([Figure 4c](#fig4){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}). Significant decreases in both the number of osteoblasts per bone perimeter (p=0.05) and bone formation rate (p=0.0046) were observed only at 2 months, and not at 13 months. However, in vitro osteoblast differentiation from bone marrow mesenchymal cells harvested at 2--3 months did not differ by genotype ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Osteoclast numbers per bone perimeter were slightly increased in Fndc5-transgenic mice versus wild type across 2--13 months but did not reach statistical significance ([Figure 4c](#fig4){ref-type="fig"}). However, primary bone marrow progenitors isolated from *Fndc5-*transgenic mice at 2--3 months demonstrated markedly greater osteoclastogenic potential compared to the wild type, yielding significantly higher numbers of osteoclasts that were qualitatively larger than controls during in vitro differentiation (p\<0.0001; [Figure 4d](#fig4){ref-type="fig"}, [Source data 1](#sdata1){ref-type="supplementary-material"}).

![Skeletal phenotype and osteoclastogenic potential of *Fndc5* forced expression with McK muscle promoter mice (MCK-FNDC5, TG) compared to wild type C57BL/6J controls (WT).\
Whole-bone gene expression from tibia shows increased *Fndc5* expression out to 13 months (**a**, N = 3--5). Representative transverse slice images of trabecular bone at the midpoint of the distal femoral metaphysis (left) and cortical bone at the mid-diaphysis (right) demonstrates reduced cortical bone area in TG versus WT, especially at early ages, with trabecular BV/TV significantly lower at 2 and 4.5 months, and cortical thickness significantly lower at 2 months (**b**, N = 6). Tibial histomorphometry at 2 and 13 months demonstrated reduction of bone volume fraction at both time points, with slight increase in osteoclast numbers in tibia at 13 months (**c**, N = 6). In vitro MCSF/RANKL-induced osteoclast differentiation from bone marrow progenitors at 2--3 months of age yielded higher osteoclast numbers in TG versus WT (**d**, N = 8). \*\*\*p\<0.001, \*\*\*\*p\<0.0001 versus WT.](elife-58172-fig4){#fig4}

This study demonstrates that irisin plays an important role in regulating bone remodeling not only by stimulating osteoblasts and osteocytes as previously described, but by also directly acting on osteoclasts to promote differentiation and resorption. This stimulatory effect was observed across multiple experiments with primary murine progenitors and the RAW 264.7 macrophage cell line and occurred with either intermittent or continuous irisin exposure across a range of physiologic concentrations previously reported in humans ([@bib13]). Analogous to its action on osteocytes, we confirmed the expression of integrin subunits α~V~ and β~5~ on osteoclasts and identified it as a likely receptor for irisin, particularly since blocking this receptor complex with a neutralizing antibody completely suppressed the stimulatory effect of irisin on osteoclastogenesis ([Figure 1](#fig1){ref-type="fig"}). Furthermore, we found that both recruitment and differentiation of more osteoclast progenitors with irisin treatment appeared to be driving factors of enhanced bone resorption, based on in situ studies on native dentin as well as synthetic calcium phosphate and collagen substrates ([Figure 2](#fig2){ref-type="fig"}). Using unbiased RNAseq analysis and qRT-PCR of irisin-treated osteoclasts, we noted that some markers of early osteoclast differentiation, nuclear fusion markers, and enzymes related to bone resorption were upregulated, matching the functional effects observed in vitro. In addition, several osteoclast-secretory factors known to stimulate osteoblasts were significantly upregulated, suggesting that the direct actions of irisin on this cell type may have further impact on cell signaling to enhance coupled remodeling ([Figure 3](#fig3){ref-type="fig"}).

To confirm the capacity of irisin to impact osteoclast function in vivo, we employed a genetic strategy with chronically forced expression of *Fndc5* using the muscle-specific *Mck* promoter. In that mouse model, we demonstrated that high levels of irisin were expressed in the whole bone marrow at both ages, and this was associated with low bone mass. The relative contribution of osteoclastogenesis to the skeletal phenotype cannot be resolved in our genetic model. While early decreases in osteoblast numbers and bone formation rate were observed by histomorphometry at 2 months of age in the transgenic mouse, these metrics became equivalent to controls at 13 months, whereas a trend for increased osteoclast numbers was noted at 13 months. The in vitro differentiation cultures from the *Fndc5*-transgenic marrow progenitors from 2- to 3-month-old mice provide further supportive evidence for the action of irisin on the osteoclast. Bone marrow mesenchymal progenitors from *Fndc5*-transgenic mice at 2--3 months of age were not different from the wild type in regard to the pace or quantitation of osteoblast differentiation or mineralization. On the other hand, in vitro osteoclastogenesis from transgenic hematopoietic progenitors was markedly enhanced compared to control mice ([Figure 4](#fig4){ref-type="fig"}). Additionally, we have found that continuous exogenous treatment with 10 ng/mL irisin used to stimulate in vitro osteoclast differentiation from wild type progenitors had no observable effect on osteoblast differentiation or mineralization ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Taken together, our results demonstrate a clear action of irisin on the osteoclast, but further suggest that in this forced expression model, irisin may act at early stages to reduce bone mass by suppressing osteoblast-mediated bone formation, while the later and persistent effects on bone turnover may be more focused on the osteoclast.

While our observations of irisin's effects on osteoblastogensis differ from other published studies ([@bib4]), it is important to note that both dose and duration of irisin exposure may be critical determinants of the skeletal response and hence be responsible for phenotypic differences. For example, from our gene expression studies, it is clear that the activity of the *Mck* promoter for *Fndc5* is very high at 2 months but waned with age, albeit still maintaining relatively increased levels ([Figure 4a](#fig4){ref-type="fig"}). This exposure difference may impact skeletal cell responsiveness as noted by an earlier study demonstrating suppressed osteoclastogenesis in vitro with supraphysiologic levels of irisin ([@bib17]). Similarly, we found that 20 ng/mL irisin had little effect on osteoclast number in vitro ([Figure 1b](#fig1){ref-type="fig"}), and initial experiments with doses of irisin equal or exceeding 100 ng/mL actually showed reduced osteoclast numbers (data not shown). Our previous work demonstrated that irisin concentrations in humans are approximately 2--4 ng/mL but increase to 10 ng/mL or more with exercise, a dose range we employed for the in vitro studies ([@bib13]). Thus, both dosing and timing relative to developmental age may be determinants of irisin's function as a dynamic signaling molecule in the skeleton, and its actions on specific bone cell types. It should be noted that the relatively narrow dose range for stimulating osteoclastogenesis could have physiologic implications since exercise induces rapid changes in serum calcium ([@bib19]). If irisin targets both osteoclasts and osteocytes, it may serve as another counter-regulatory hormone to maintain serum calcium during the early phases of exercise much like parathyroid hormone ([@bib19]).

Taken together, our studies provide more evidence that irisin mediates muscle-bone crosstalk by regulating bone remodeling. While further studies are necessary to fully elucidate irisin's mechanism of action on the osteoclast and to resolve contrasting cellular effects observed between cell types and experimental models, it remains clear that this myokine is a potent regulator of bone remodeling that is able to both act directly on all key cell types of the bone remodeling unit, and potentially modulate signaling between them.

Materials and methods {#s3}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                  Designation                             Source or reference    Identifiers                                                                                     Additional\
  (species) or resource                                                                                                                                                                         information
  ------------------------------ --------------------------------------- ---------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------
  Strain, strain background\     C57BL/6J                                Jackson Laboratories   IMSR Cat\# JAX:000664, RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   Wild type mouse line
  (*Mus musculus* male/female)                                                                                                                                                                  

  Cell line\                     RAW 264.7                               ATCC                   TIB-71                                                                                          Cryopreserved monocyte cell line
  (*Mus musculus)*                                                                                                                                                                              

  Antibody                       Anti-Integrin aVb5 (Mouse monoclonal)   Abcam                  ab78289, RRID:[AB_1566022](https://scicrunch.org/resolver/AB_1566022)                           Neutralizing antibody (1:1000)

  Peptide, recombinant protein   Irisin                                  Lake Pharma [@bib14]   N/A (custom)                                                                                    10 his-tag recombinant from HEK 293 cells

  Peptide, recombinant protein   RANKL, recombinant human                PeproTech              310--01                                                                                         Osteoclast growth factor

  Peptide, recombinant protein   M-CSF, recombinant murine               PeproTech              315--02                                                                                         Osteoclast growth factor

  Commercial assay or kit        Acid Phosphatase Kit                    Sigma-Aldrich          387A                                                                                            TRAP assay

  Commercial assay or kit        Corning Osteo Assay                     VWR                    89184--614                                                                                      Resorption assay

  Commercial assay or kit        OsteoLyse Assay Kit                     Lonza                  PA-1500                                                                                         Resorption assay

  Software, algorithm            Prism 8                                 Graphpad               RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                                    Statistics/graphing software

  Software, algorithm            FIJI                                    NIH                    RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)                                    Image analysis software
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Primary osteoclast culture {#s3-1}
--------------------------

Primary murine osteoclasts were differentiated and cultured in vitro by the following methods. Bone marrow was collected via centrifugation from the femur and tibia of 8-week-old male C57BL6/J mice and cultured in αMEM (VWR, Radnor, PA) supplemented with 10% fetal bovine serum VWR) and 1% Pen-Strep (VWR). After 48 hr, non-adherent hematopoietic progenitor cells were removed and plated at 1.563 × 10^5^ cell/cm^2^ in 96-well tissue culture plates for cell counting or in 12-well tissue culture plates for RNA extraction. Osteoclast differentiation was stimulated by supplementation with 30 ng/mL M-CSF (PeproTech, Rocky Hill, NJ) and 100 ng/mL RANKL (PeproTech; [@bib17]), with 200 µL or 2 mL media refreshed at days 3 and 5 after plating for 96- and 12-well plates, respectively. Irisin was produced in HEK 293 cells as a 10 His-tag recombinant, via previously established protocols (Lake Pharma, Hopkinton, MA; [@bib14]), and supplemented continuously in the media at 10 ng/mL, or as otherwise indicated.

Primary source gender and cell line confirmations {#s3-2}
-------------------------------------------------

We used 8-week-old male C57BL6/J mice as the primary cell source for all experiments unless otherwise stated. Confirmation of irisin effect on osteoclastogenesis was also established in female C57BL6/J mice to compare gender among this wild type murine primary source of progenitors, which were cultured and counted as described. Additionally, the RAW 264.7 macrophage cell line (ATCC TIB-71, Manassas, VA) was employed as a non-primary cell source, following previously published protocols for osteoclast differentiation from this cell line ([@bib19]; [@bib2]). Briefly, RAW cells were played at a lower density in 96-well plates of 6 × 10^3^ cells/well and cultured as described, but for the exclusion of MCSF in the media. The RAW 264.7 cell line is not included in the database of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee; identity authentication via STR profiling and a negative mycoplasma contamination test were performed by the supplier ATCC.

Osteoclast counts {#s3-3}
-----------------

At day 7, 96-well plates were fixed in 10% formalin and stained for TRAP (Acid Phosphatase Kit, Sigma-Aldrich, St Louis, MO) to visualize and count mature osteoclast numbers, where a TRAP-positive cell with three or more nuclei was defined as an osteoclast. Initial counting was performed via manual counting on an inverted microscope, with confirmative counts performed by manually counting blinded copies of composite images of each sample in ImageJ (Blind Analysis, Labcode).

Integrin antibody blocking {#s3-4}
--------------------------

A separate experiment employed the culture and counting methods described above for irisin treatment in combination with a neutralizing antibody for integrin α~V~β~5~ (Anti-Integrin aVb5 antibody, Abcam, Cambridge, UK) and an IgG control (Mouse IgG1 Isotype Control, R and D Systems, Minneapolis, MN), each supplied continuously in the media during the 7-day culture at 0.9 µg/mL.

Resorption assays {#s3-5}
-----------------

Multiple resorption assays were utilized to characterize and confirm the effect of irisin treatment on osteoclast resorptive capacity. The primary approach employed decellularized dentin slices as a native bone substrate. Hematopoietic progenitors were plated on the bone slices at 3 × 10^5^ cell/cm^2^ in a 50 µL place on the top of the slice in a 10 mm Petri dish and incubated for 30 min to facilitate cell adhesion to the substrate alone. Slices were then moved into 96-well plates and cultured as described above. At day 7, dentin slices were TRAP stained and imaged as described for osteoclast counts. TRAP+ osteoclasts were visualized on the dentin surface via a top-down microscope used for histomorphometry analysis, with bright light illumination provided from below, through the thin dentin slice. To image the underlying resorption pits, the dentin slices were then sonicated briefly to removed cells and stained with toluidine blue to visualize resorption pits by previously published methods ([@bib23]) on the same microscope. Briefly, each slice was placed face-down on a 20 µL drop of 1% toluidine blue solution (in 1% sodium borate 10-hydrate solution with distilled water) for 4 min and then rinsed and allowed to air dry before imaging and manual calculation of total pit areas for blinded images in ImageJ. Toluidine-stained pits were clearly identifiable on the dentin surface as rounded features with dark edges and were manually traced in Image J to generate binary thresholded masks from which the total area was calculated. Confirmation experiments were performed with the Osteo Assay resorption assay (Corning Inc, Corning, NY), whereby osteoclasts were cultured on the substrate treated 96-well plates by the previously described methods, then removed with 10% bleach and the substrate was stained with von Kossa stain (Sigma-Aldrich). Imaging of the wells on a dissecting scope with backlighting allowed visualization of pits, and automated area calculations based on binary thresholded masks of the images. To determine earlier time-point resorption, the OsteoLyse assay (Lonza, Basel, Switzerland) was employed, utilizing the same osteoclast culture methods on a collagen substrate, whereby detection of carboxy-terminal collagen crosslinks (CTX) allows for relative quantification of degraded collagen as an indicator of resorptive activity. Aliquots of the media at day 3 in culture were analyzed via ELISA for relative fluorescence indicative of CTX release and normalized to undifferentiated and no-cell controls.

Gene expression analysis {#s3-6}
------------------------

Total RNA was isolated from osteoclast cells cultured with or without 10 ng/mL irisin for 7 days with the Trizol reagent (ThermoFisher, Waltham, MA) and RNeasy mini kit (Qiagen, Hilden, Germany), with mRNA enrichment from 100 ng of total purified RNA and Illumina sequencing libraries preparation performed using Kapa stranded mRNA Hyper Prep (Roche Sequencing Solutions, Pleasanton, CA). Gene libraries were multiplexed in an equimolar pool and were sequenced on an Illumina NextSeq 500 with single-end 75 bp reads. Raw reads were aligned to the UCSC mm10 reference genome using a STAR aligner ([@bib9]; version STAR_2.4.2a), and raw gene counts were quantified using the quantMode GeneCounts flag. Differential expression testing was performed using Limma ([@bib22]) and DESeq2 ([@bib16]). RNAseq analysis was performed using the VIPER snakemake pipeline ([@bib7]). Follow-up RT-qPCR was performed on RNA from a separate set of osteoclasts for markers identified via RNAseq and additional targets for differentiation, resorption, and clastokines with primer sequences obtained PrimerBLAST (NCBI-NIH), using reverse transcriptase kit (Qiagen) and AzuraQuant Green Fast PCR Mix (Azura Genomics, Rynam, MA) with an IQ PCR detection system (Bio-Rad, Hercules, CA). Gene expression data were analyzed via the comparative Ct method, utilizing *Hprt* as the housekeeping gene and normalizing by untreated control mean Ct.

Forced expression of Fndc5 in the murine muscle {#s3-7}
-----------------------------------------------

Transgenic C57BL/6J mice with forced expression of *Fndc5* were generated and generously gifted by Dr Eric Olson of UT Southwestern. The *Mck* promoter was utilized as previously demonstrated to induce skeletal muscle-specific forced expression of *Fndc5* ([@bib15]). Microarchitecture of distal trabecular bone and midshaft cortical bone was analyzed at 2, 4.5, and 14 months by µCT and at 2 and 13 months by dynamic histomorphometry, with measures performed and analyzed according to standard nomenclatures.

The µCT was performed with a high-resolution desktop micro-tomographic imaging system (µCT40, Scanco Medical AG, Brüttisellen, Switzerland) to assess trabecular bone microarchitecture and cortical bone morphology in the femoral distal metaphysis and mid-diaphysis, respectively. Scans were acquired with a 10 µm^3^ isotropic voxel size, 70 kVP, 114 mAs, 200 ms integration time, subjected to Gaussian filtration and segmentation. Transverse distal femur slices were evaluated in a region beginning 200 µm above the peak of the distal growth plate and extending proximally 1500 µm (150 slices). The trabecular bone region was identified by semi-manually tracing the region of interest with assistance from an auto-contouring software algorithm. Images were thresholded with an adaptive-iterative algorithm ([@bib21]; [@bib18]; [@bib20]). The average adaptive-iterative threshold of the 4.5-month *Fndc5*-transgenic mice (232 mgHA/cm^3^) was used for all groups as the threshold to segment bone from soft tissue. Morphometric variables were computed from binarized images using established direct 3D techniques independent of assumptions about the underlying structure ([@bib11]; [@bib12]; [@bib1]). Cortical bone parameters were assessed from 50 transverse µCT slices obtained at the femoral mid-diaphysis using a 10 µm isotropic voxel size. The ROI, including all pixels within the outermost edge of the cortex, was subjected to Gaussian filtration and segmented using a fixed threshold of 700 mgHA/cm^3^.

Dynamic histomorphometry was performed on fixed right tibiae, dehydrated with acetone, and embedded in methylmethacrylate. Undecalcified 4-µm-thick sections were obtained by microtome and stained with von Kossa, with consecutive sections left unstained fluorescence label analysis and stained with toluidine blue for identification of osteoblasts and osteoid. Additional consecutive sections were stained with tartrate-resistant acid phosphatase (TRAP) and counterstained with toluidine blue for identification of osteoclasts. Histomorphometric analysis was performed in the proximal tibia under 200× magnification in a 0.9 mm by 1.3 mm wide region 200 µm away from the growth plate using OsteoMeasure (Osteometrics Inc, Decatur, GA). Structural parameters were obtained from three consecutive sections and averaged. Structural, dynamic, and cellular parameters were calculated and expressed according to the standardized nomenclature ([@bib8]).

Additional femur and tibia were pulverized at 4.5 and 13 months with RNA extraction and subsequent gene expression analysis was performed via previously described protocols. Bone marrow isolation and in vitro osteoclast cultures were performed via previously described protocols. In vitro osteoblast cultures were performed by previously established protocols from the same adherent mesenchymal cell population of the same bone marrow isolations from wild type and transgenic mice used for osteoclast cultures. Briefly, after removal of non-adherent hematopoietic progenitors from culture flask for osteoclast culture, adherent mesenchymal progenitors were trypsinized and plated at 1 × 10^6^ cell/well in 6-well plates with three replicates per group, and cultured in αMEM supplemented with 10% fetal bovine serum and 1% Pen-Strep until confluent. Confluent cells were then cultured for 18 days, supplemented with β-glycerol phosphate (Sigma-Aldrich) and ascorbic acid (Sigma-Aldrich), and stained for cell proliferation with crystal violet stain (Sigma-Aldrich), differentiation with an alkaline phosphatase kit (Sigma-Aldrich), and mineralization with von Kossa staining (silver nitrate, Sigma-Aldrich). All experiments were conducted with six age-matched female mice.

Experimental design and data analysis {#s3-8}
-------------------------------------

Isolation of primary murine bone marrow was conducted by pooling tissue from the maximum available number of same-gender littermates (N = 3--5). For in vitro cultures, the adequate number of biological replicates (replicate wells in a tissue culture plastic plate, or slices of dentin) was determined via power analyses based on preliminary data (α = 0.05, power = 0.8) as six, and so osteoclast counting and resorption experiments were conducted in triplicate with representative experiments shown, with 6--8 replicate wells per group in each experiment ([Figure 1b,c,d,e,g](#fig1){ref-type="fig"}, [Figure 2c,d](#fig2){ref-type="fig"}, [Figure 4d](#fig4){ref-type="fig"}). Similarly, gene expression analysis via RT-qPCR was conducted for duplicate repeat experiments with three biological replicates per group and two technical replicates (replicate wells read per sample and averaged), with pooled representative data for a sample number of six ([Figure 1f](#fig1){ref-type="fig"}, [Figure 3b](#fig3){ref-type="fig"}, [Figure 4a](#fig4){ref-type="fig"}). Due to limitations in the availability of dentin slices, this resorption experiment was conducted once with a sample size of five per group ([Figure 2a](#fig2){ref-type="fig"}), and was thus followed up with additional commercially available resorption assays ([Figure 2c,d](#fig2){ref-type="fig"}). Similarly, RNA sequencing analysis was performed on a separate experimental set with three biological replicates per group ([Figure 3a](#fig3){ref-type="fig"}). For characterization of the *Fndc5*-transgenic mouse, power analyses based on previous outcome metrics from histomorphometry and gene expression in the *Fndc5*-null mouse experiments ([@bib14]; α = 0.05, power = 0.8) indicated an adequate sample size of six mice per group, which was employed for in vivo characterization of bone properties based on the availability of same-gender age-matched mice ([Figure 4b,c](#fig4){ref-type="fig"}), while in vitro culture of osteoclast progenitors from these mice were carried out with bone marrow isolates from maximal number of same-gender littermates (N = 3--5) and eight replicate wells of osteoclast differentiation cultures per group ([Figure 4d](#fig4){ref-type="fig"}).

For statistical analysis, outlier identification was first performed via Grubb's test with α = 0.05. Based on the recommended guidelines for analysis, comparisons between two groups alone (irisin versus control osteoclast counts, resorption, gene expression) was conducted via unpaired, two-tailed t-test, p\<0.05, while multiple group comparisons were made via ordinary one-way (irisin dose and duration versus control) or two-way (antibody/irisin treatment osteoclast counts) ANOVA with Tukey post-hoc analysis and p\<0.05. RNA sequencing data analysis was performed as described above with statistical significance via the Wald test with the Benjamini-Hochberg adjustment. Quantitative data are represented graphically as mean ± standard deviation with individual values overlaid.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The reviewers determined that is a well-designed study of the effects of Irisin on osteoclastogenesis. Using a combination of in vitro, RNAseq, and in vivo studies (transgenic mouse model over-expressing Fndc5, an upstream regulator of Irisin in response to exercise), this work provides strong evidence that, in addition to its known effects on osteoblasts and osteocytes, irisin directly regulates osteoclasts and that the hematopoietic progenitors were biased towards osteoclast differentiation.

**Decision letter after peer review:**

Thank you for submitting your article \"Irisin directly stimulates osteoclastogenesis and bone resorption in vitro and in vivo\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kathryn Cheah as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Warren Grayson (Reviewer \#2); Sundeep Khosla (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

This is a well-designed study of the effects of Irisin on osteoclastogenesis that reports the effects of dosing and timing of Irisin on osteoclast number, morphology, and integrin α~V~β~5~ expression in vitro. Using a combination of in vitro, RNAseq, and in vivo studies (transgenic mouse model over-expressing Fndc5, an upstream regulator of Irisin in response to exercise), the authors provide strong evidence that, in addition to its known effects on osteoblasts and osteocytes, irisin directly regulates osteoclasts. The authors also found that the hematopoietic progenitors were biased towards osteoclast differentiation along with an increase in some resorption markers and clastokines. The reviewers noted that the lack of mechanistic insights is a major limitation of the study (as also acknowledged by the authors).

Essential revisions:

1\) The authors should show validation of the transgenic mouse in terms of the quantitative changes in Fndc5 or Irisin expression. This is important given that the in vivo data contradicts to the previously published results that reported Irisin increases bone mass and cortical bone thickness. In this study, the authors have observed a decrease in osteoblasts and an increase in osteoclasts and concomitant decrease in mineralized surface (MS/BS).

2\) Another concern is related to the bone histomorphometry (Figure 4B). There is a clear reduction in BV/TV, which seems to be driven more by a reduction in the MS/BS and osteoblast numbers (p values close to 0.05) than by increased osteoclast numbers. The increase in osteoclast progenitors in the FNDC5 Tg mice is consistent with the authors\' hypothesis. The authors should address this in the Discussion -- perhaps the most likely explanation is that there may be a more robust increase in bone resorption and osteoclast numbers earlier in life (the mice were analyzed at 4.5 months). If data on younger mice are available, these should be provided; if not, this issue should at least be discussed.
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Author response

> Summary:
>
> This is a well-designed study of the effects of Irisin on osteoclastogenesis that reports the effects of dosing and timing of Irisin on osteoclast number, morphology, and integrin α~V~β~5~ expression in vitro. Using a combination of in vitro, RNAseq, and in vivo studies (transgenic mouse model over-expressing Fndc5, an upstream regulator of Irisin in response to exercise), the authors provide strong evidence that, in addition to its known effects on osteoblasts and osteocytes, irisin directly regulates osteoclasts. The authors also found that the hematopoietic progenitors were biased towards osteoclast differentiation along with an increase in some resorption markers and clastokines. The reviewers noted that the lack of mechanistic insights is a major limitation of the study (as also acknowledged by the authors).

The authors thank the editors and reviewers for their time in considering this manuscript. In response to the summary, we acknowledge the lack of in-depth mechanistic insights in this study but note the novelty of these findings in regard to previously uncharacterized effects of irisin on a key cell type in bone homeostasis, the osteoclast. We therefore feel that the study stands on its own while also setting the foundation for more detailed mechanistic studies that are currently in planning and underway. Below, we address each of the specific critiques in turn, with rationale and reference to corresponding changes in the revised manuscript.

> Essential revisions:
>
> 1\) The authors should show validation of the transgenic mouse in terms of the quantitative changes in Fndc5 or Irisin expression.

We have now revised Figure 4 to more clearly demonstrate the validation of the transgenic forced expression of FNDC5 by showing quantitative increases in whole-bone mRNA expression of FNDC5 in tibia at both 4.5 and 13 months of age (Figure 4A). To establish the characterization of this transgenic model more completely we have further included data at earlier and later timepoints where available, at 2 and 13 months for µCT (Figure 4B) and at 13 months for histomorphometry (Figure 4C) (see Results and Discussion, fifth paragraph).

> This is important given that the in vivo data contradicts to the previously published results that reported Irisin increases bone mass and cortical bone thickness. In this study, the authors have observed a decrease in osteoblasts and an increase in osteoclasts and concomitant decrease in mineralized surface (MS/BS).

To more fully explore the respective roles of osteoblasts and osteoclasts in this model we have included the additional histomorphometry data at 13 months of age (Figure 4C) as well as in vitro osteoblast cultures carried out from both wild type bone marrow progenitors with exogenous irisin treatment (Figure 1---figure supplement 1) and compared wild type and transgenic bone marrow progenitors (Figure 1---figure supplement 1). We have endeavored to address contradictions with previously published results throughout the Discussion (Results and Discussion, eighth paragraph).

> 2\) Another concern is related to the bone histomorphometry (Figure 4B). There is a clear reduction in BV/TV, which seems to be driven more by a reduction in the MS/BS and osteoblast numbers (p values close to 0.05) than by increased osteoclast numbers. The increase in osteoclast progenitors in the FNDC5 Tg mice is consistent with the authors\' hypothesis. The authors should address this in the Discussion -- perhaps the most likely explanation is that there may be a more robust increase in bone resorption and osteoclast numbers earlier in life (the mice were analyzed at 4.5 months). If data on younger mice are available, these should be provided; if not, this issue should at least be discussed.

Thank you for that important point about the lower bone mass. We have now included µCT data for an earlier time point at 2 months, which does indeed also show a reduction in trabecular and cortical bone, and smaller bone area in transgenic mice. We have added the histomorphometry data at this earlier time point to gain insight into osteoblasts and osteoclasts relative to bone changes. In sum for the revised manuscript we included µCT at three time points (2, 4.5 and 13 months) and dynamic histomorphometry at two time points (2 months and 13 months). The original submission noted that histomorphometry was done at 4.5 months; that was in error, it was performed on 2-month-old mice and corresponds with the µCT at that time point. As noted, we have now also included in vitro osteoblast differentiation cultures of bone marrow mesenchymal progenitors from 2-3-month wild type and transgenic mice and found no increase in osteoblast differentiation or mineralization (Figure 4---figure supplement 1). Similarly, in vitro osteoblast differentiation of wild type bone marrow progenitors showed no effect of the continuous exogenous treatment with 10 ng/mL irisin that was shown to stimulate osteoclast differentiation (Figure 1---figure supplement 1).

These in vitro osteoblast findings have been included in the Discussion to inform interpretation on the respective roles on osteoblasts and osteoclasts in the transgenic model. In the transgenic model itself, the decrease in osteoblast numbers and bone formation at 2 months did not persist at 13 months, when it showed a slight but nonsignificant increase possibly related to the increase in osteoclast number (Figure 4C). At the earlier time points, osteoclast numbers did not differ by genotype, whereas by 13 months, there were more osteoclasts per bone surface in the transgenic. While the level of irisin exposure with exogenous treatment in vitro and forced FNDC5 expression in vivo are not directly comparable, these data together suggest that irisin influences both osteoblast and osteoclast differentiation throughout skeletal development. A more complete discussion of these data and the insights they may provide into the respective roles of osteoblasts and osteoclasts in response to irisin have been worked into the Discussion (Results and Discussion, eighth paragraph).
